Publicaciones en colaboración con investigadores/as de Hôpital Européen Georges-Pompidou (83)

2024

  1. Characterization of Responses to Lenvatinib plus Pembrolizumab in Patients with Advanced Renal Cell Carcinoma at the Final Prespecified Survival Analysis of the Phase 3 CLEAR Study

    European Urology

  2. Early versus delayed coronary angiography in patients with out-of-hospital cardiac arrest and no ST-segment elevation: a systematic review and meta-analysis of randomized controlled trials

    Clinical Research in Cardiology, Vol. 113, Núm. 4, pp. 561-569

  3. Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1)

    British Journal of Cancer, Vol. 130, Núm. 3, pp. 434-441

  4. Secondary Prevention Therapies in Real-World Patients with Myocardial Infarction: Eligibility Based on Randomized Trials Supporting European and American Guidelines

    American Journal of Medicine, Vol. 137, Núm. 2, pp. 137-146.e10

2023

  1. Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry

    European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 42-53

  2. Care of patients with ST-elevation myocardial infarction: an international analysis of quality indicators in the acute coronary syndrome STEMI Registry of the EURObservational Research Programme and ACVC and EAPCI Associations of the European Society of Cardiology in 11 462 patients

    European Heart Journal: Acute Cardiovascular Care, Vol. 12, Núm. 1, pp. 22-37

  3. Economic evaluation of restrictive vs. liberal transfusion strategy following acute myocardial infarction (REALITY): trial-based cost-effectiveness and cost-utility analyses

    European heart journal. Quality of care & clinical outcomes, Vol. 9, Núm. 2, pp. 194-202

  4. Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy

    Kidney International Reports, Vol. 8, Núm. 12, pp. 2754-2764

  5. Glomerular diseases in pregnancy: pragmatic recommendations for clinical management

    Kidney International, Vol. 103, Núm. 2, pp. 264-281

  6. Impact of standard modifiable cardiovascular risk factors on 2-year all-cause mortality: Insights from an international cohort of 23,489 patients with acute coronary syndrome

    American Heart Journal, Vol. 264, pp. 20-30

  7. TransFAIR study: a European multicentre experimental comparison of EHR2EDC technology to the usual manual method for eCRF data collection

    BMJ health & care informatics, Vol. 30, Núm. 1

  8. Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma

    European Urology

2022

  1. ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up

    European Heart Journal, Vol. 43, Núm. 11, pp. 1059-1103

  2. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    Cardiovascular research, Vol. 118, Núm. 6, pp. 1385-1412

  3. European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis

    European Heart Journal, Vol. 43, Núm. 11, pp. 1033-1058

  4. ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

    Scientific Data, Vol. 9, Núm. 1

  5. Sex differences in mortality after an acute coronary syndrome increase with lower country wealth and higher income inequality

    Revista Espanola de Cardiologia, Vol. 75, Núm. 5, pp. 392-400

2021

  1. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial

    The Lancet Oncology, Vol. 22, Núm. 4, pp. 525-537

  2. An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with european society of cardiology working group on coronary pathophysiology & microcirculation endorsed by coronary vasomotor disorders international study group

    EuroIntervention, Vol. 16, Núm. 13, pp. 1049-1069

  3. Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events among Patients with Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial

    JAMA - Journal of the American Medical Association, Vol. 325, Núm. 6, pp. 552-560